Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Reagan

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|April 4, 2020
Asciminib in Relapsed Chronic Myeloid LeukemiaIlyas Sahin, John L Reagan
Cancers|August 26, 2023
Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future ProgressAdel Chergui, John L Reagan
Hematology/Oncology Clinics of North America|April 3, 2012
Why is my patient neutropenic?John L Reagan, Jorge J Castillo
Future Oncology (London, England)|June 21, 2014
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemiaJohn L Reagan, Jorge J Castillo
Expert Review of Anticancer Therapy|February 24, 2011
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemiaJohn L Reagan, Jorge J Castillo
Blood|December 24, 2016
Hodgkin lymphoma mimicking lung abscessAndrew E Foderaro, John L Reagan
Thescientificworldjournal|March 29, 2011
Plasmablastic lymphoma: a systematic reviewJorge J Castillo, John L Reagan
Oncotargets and Therapy|December 13, 2018
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemiaPamela C Egan, John L Reagan
Journal of Hematopathology|July 10, 2025
Unicentric Castleman disease following POEMS syndrome remissionSovijja Pou, Shelby Smith, John L Reagan
Cureus|June 12, 2018
Pruritic Rash in a Patient with Hodgkin's LymphomaAudrey Le, Dimitrios Farmakiotis, John L Reagan
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|April 4, 2020
Asciminib in Relapsed Chronic Myeloid LeukemiaIlyas Sahin, John L Reagan
Cancers|August 26, 2023
Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future ProgressAdel Chergui, John L Reagan
Hematology/Oncology Clinics of North America|April 3, 2012
Why is my patient neutropenic?John L Reagan, Jorge J Castillo
Future Oncology (London, England)|June 21, 2014
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemiaJohn L Reagan, Jorge J Castillo
Expert Review of Anticancer Therapy|February 24, 2011
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemiaJohn L Reagan, Jorge J Castillo
Blood|December 24, 2016
Hodgkin lymphoma mimicking lung abscessAndrew E Foderaro, John L Reagan
Thescientificworldjournal|March 29, 2011
Plasmablastic lymphoma: a systematic reviewJorge J Castillo, John L Reagan
Oncotargets and Therapy|December 13, 2018
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemiaPamela C Egan, John L Reagan
Journal of Hematopathology|July 10, 2025
Unicentric Castleman disease following POEMS syndrome remissionSovijja Pou, Shelby Smith, John L Reagan
Cureus|June 12, 2018
Pruritic Rash in a Patient with Hodgkin's LymphomaAudrey Le, Dimitrios Farmakiotis, John L Reagan
Pageof 8